Clinical Trials Browser

OTHER × Immunoblastic Lymphadenopathy × spartalizumab × Clear all

NCT05821192 2023-04-20

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

Phase NA Unknown

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell